Skip to main content
SpringerLink
Log in

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Combination chemotherapy regimens can improve survival in patients with advanced gastric and oesophageal adenocarcinoma. Docosahexaenoic acid (DHA)-paclitaxel is a novel conjugate formed by the covalent linkage of the fatty acid DHA to paclitaxel and may result in increased tumour exposure to paclitaxel without increased toxicity.

Patients and methods

In this single arm, phase II study of DHA-paclitaxel, eligible patients with previously untreated, inoperable locally advanced or metastatic adenocarcinoma of the oesophagus, oesophago-gastric junction or stomach were treated with DHA-paclitaxel (1,100 mg/m2) administered by 2-h intravenous infusion every 21 days.

Results

Fifty-four patients were recruited of whom 53 were evaluable for toxicity, and 48 for response. There were five confirmed partial responses (9.4%) by the RECIST criteria. The median duration of response was 87 days (range 49–97 days), the median time to progression was 84 days (95% CI 78–124 days), and median overall survival was 262 days (95% CI 205–357 days). Grade ≥3 neutropaenia occurred in 93% of patients, and febrile neutropaenia in 17% of patients.

Conclusions

DHA-paclitaxel has modest activity in patients with oesophago-gastric cancer and with haematological toxicity that is comparable to paclitaxel and docetaxel.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Allum WH, Powell DJ, McConkey CC, Fielding JW (1989) Gastric cancer—a 25-year review. Br J Surg 76:535–540

    Article  PubMed  CAS  Google Scholar 

  2. Medical Research Council Oesophageal Working Party (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 359:1727–1733

    Google Scholar 

  3. Murad AM, Santiago FF, Petroianu A, et al (1993) Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72:37–41

    Article  PubMed  CAS  Google Scholar 

  4. Glimelius B, Hoffman K, Haglund U, et al (1994) Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189–190

    PubMed  CAS  Google Scholar 

  5. Pyrhonen S, Kuitonen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591

    PubMed  CAS  Google Scholar 

  6. Findlay M, Cunningham D, Norman A, et al (1994) A phase II study in advanced gastro-oesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5:609–616

    PubMed  CAS  Google Scholar 

  7. Webb A, Cunningham D, Scarffe JH, et al (1997) Randomised trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267

    PubMed  CAS  Google Scholar 

  8. Schoffski P (2002) New drugs for treatment of gastric cancer. Ann Oncol 13(Suppl 4):13–22

    PubMed  Google Scholar 

  9. Polee MB, Hop WC, Kok TC (2003) Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer 89:2045–2050

    Article  PubMed  CAS  Google Scholar 

  10. Sauer LA, Stayman JW III, Dauchy RT (1982) Amino acid, glucose, and lactic acid utilization in vivo by rat tumors. Cancer Res 42:4090–4097

    PubMed  CAS  Google Scholar 

  11. Sauer LA, Dauchy RT (1990) Tumour-host metabolic inter-relationships. Biochem Soc Trans 18:80–82

    PubMed  CAS  Google Scholar 

  12. Sauer LA, Dauchy RT (1992) Uptake of plasma lipids by tissue-isolated hepatomas 7288CTC and 7777 in vivo. Br J Cancer 66:290–296

    PubMed  CAS  Google Scholar 

  13. Bradley MO, Webb NL, Anthony FH, et al (2001) Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7:3229–3238

    PubMed  CAS  Google Scholar 

  14. Wolff AC, Donehower RC, Carducci MK, et al (2003) Phase I study of docosahexaenoic acid-paclitaxel: a fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9:3589–3597

    PubMed  CAS  Google Scholar 

  15. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  16. Kaplan EL, Meier P, et al (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  17. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10

    Article  PubMed  CAS  Google Scholar 

  18. Ajani JA, Fairweather J, Dumas P, et al (1998) Phase II trial of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4:269–274

    PubMed  CAS  Google Scholar 

  19. Kelsen D, Ajani J, Ilson D, et al (1994) A phase II trial of paclitaxel (taxol) in advanced esophageal cancer: preliminary report. Sem Oncol 21(5 Suppl 8):40–48

    Google Scholar 

  20. Ajani JA, Ilson DH, Daugherty K, et al (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086–1091

    Article  PubMed  CAS  Google Scholar 

  21. Mavroudis D, Kourousis C, Androulakis N, et al (2000) Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 23:341–344

    Article  PubMed  CAS  Google Scholar 

  22. Ajani JA, Ilson DH, Daugherty K, Kelsen DP (1995) Paclitaxel in the treatment of cancer of the oesophagus. Sem Oncol 22(Suppl 6):35–40

    CAS  Google Scholar 

  23. Einzig AI, Neuberg D, Remick SC, et al (1996) Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13:87–93

    Article  PubMed  CAS  Google Scholar 

  24. Sulkes A, Smyth J, Sessa C, et al (1994) Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70:380–383

    PubMed  CAS  Google Scholar 

  25. Ohtsu A, Boku N, Tamura F, et al (1998) An early phase II study of a 3-h infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21:416–419

    Article  PubMed  CAS  Google Scholar 

  26. Cascinu S, Graziano F, Cardarelli N, et al (1998) Phase II study of paclitaxel in pretreated advanced gastric cancer. Anti-Cancer Drugs 9:301–310

    Article  Google Scholar 

  27. Moiseyenko VM, Ajani J, Tjulandin SA, et al (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGCI). J Clin Oncol 23(16S):3085

    Google Scholar 

Download references

Acknowledgements

The authors are grateful to all the study staff at each of the participating centres for their support of this study.

Author information

Authors and Affiliations

  1. Centre for Oncology and Applied Pharmacology, Beatson Oncology Centre, Western Infirmary, University of Glasgow, Dumbarton Road, Glasgow, G11 6NT, UK

    Robert J. Jones & T. R. Jeffry Evans

  2. Paterson Institute for Cancer Research, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK

    Robert E. Hawkins

  3. Belfast City Hospital, Lisburn Road, Belfast, BT9 7AB, UK

    Martin M. Eatock

  4. Deanasly Centre, New Cross Hospital, Wolverhampton, WV10 0QP, UK

    David R. Ferry

  5. Department of Medical Oncology, Erasmus University Medical Centre, PO Box 2040, 3000 CA, Rotterdam, The Netherlands

    Ferry A. L. M. Eskens

  6. Internal Oncology/Hematology, Kliniken-Essen-Mitte, Henricistrasse 92, Essen, 45136, Germany

    HansJochen Wilke

Authors
  1. Robert J. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. Hawkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin M. Eatock
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David R. Ferry
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ferry A. L. M. Eskens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. HansJochen Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. R. Jeffry Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. R. Jeffry Evans.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, R.J., Hawkins, R.E., Eatock, M.M. et al. A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 61, 435–441 (2008). https://doi.org/10.1007/s00280-007-0486-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0486-8

Keywords

Search

Navigation